We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 62.50 | 60.00 | 65.00 | 62.50 | 62.50 | 62.50 | 168 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Electronic Computers | 1.03M | -2.92M | -0.2188 | -2.86 | 8.33M |
From Jul 2019 to Jul 2024
TIDMFDBK
RNS Number : 5975L
Feedback PLC
29 April 2015
29 April 2015
Feedback plc
("Feedback" or the "Company")
Drug trial and Trading update
Feedback plc (AIM: FDBK), the medical imaging software company, notes that TexRAD, its texture analysis software product will be used by Imaging Endpoints II, LLC, its exclusive partner, for imaging core lab purposes in a forthcoming drug trial in the United States. A study will shortly be commenced of colorectal cancer patients (Stage IIIc) with either Regorafenib or Standard of Care (No Treatment) after adjuvant FOLFOX. The Sponsor is US Oncology Research and the Collaborator is Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma.
Trading Update
Following the recent announcements of new sales of TexRAD, the Company announces an update on current trading.
Revenue for the current financial year ending May 2015 is expected to be in line with market expectations however due to contractual settlement costs, the product sales mix and the timing of the revenue recognition from the new TexRAD sales, the loss for the year will be higher than the current market expectations.
We continue to seek to broaden the Company's profile in the medical imaging software sector and are in active discussions with a number of potential customers for research versions of the TexRad product.
We continue to manage our limited working capital resources so as to maximise opportunities with customers and also to continue to develop the Company's products.
For further information contact:
Feedback plc Simon Barrell / Trevor Brown Tel: 01954 718072 / Tom Charlton Sanlam Securities UK (Nominated Adviser and Joint Broker) Simon Clements / Virginia Bull Tel: 020 7628 2200 Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey Tel: 020 7469 0936
This information is provided by RNS
The company news service from the London Stock Exchange
END
STRUWRNRVKASUAR
1 Year Feedback Chart |
1 Month Feedback Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
